|
- July 1, 2008 - Elixir Pharmaceuticals, Inc., today announced the Company has entered an exclusive license agreement with Boston University to key intellectual property covering discoveries regarding the use of modulators of SIRT1, a member of the sirtuin class of protein deacetylase enzymes.
|
www.physicventures.com/news/elixir-pharmaceuticals-anno...
www.physicventures.com/news/elixir-pharmaceuticals-announces-exclusive-sirtuin-intellectual-property-license-agreement-bost
|
|
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today the Company has entered into an agreement with Novartis whereby Novartis has been granted an exclusive option to acquire Elixir following the successful completion of a Phase 2a clinical study of Elixir’s lead oral ghrelin...
|
www.biospace.com/news_story.aspx?NewsEntityId=141113
|
|
|
View the Elixir Pharmaceuticals company profile on LinkedIn. See recent hires and promotions, competitors and how you’re connected to Elixir Pharmaceuticals. ... Elixir Pharmaceuticals, Inc., a pharmaceutical company, focuses on discovering, developing, and commercializing novel pharmaceuticals for the treatment of...
|
www.linkedin.com/companies/elixir-pharmaceuticals
www.linkedin.com/companies/elixir-pharmaceuticals
|
|
Elixir Pharmaceuticals Announces Issuance of SIRT Patent Covering Development of New Therapies Based on Breakthrough Science.; Business Wire ; ...Obesity CAMBRIDGE, Mass. -- Elixir Pharmaceuticals, Inc., announced today issuance...Chief Scientific Officer of Elixir Pharmaceuticals.
|
www.encyclopedia.com/doc/1G1-109990095.html
|
|
Recently, we entered into a strategic relationship with Novartis International Pharmaceuticals, or Novartis, in which it made a $10 million equity investment in Elixir through an investment fund managed by MPM Capital, ... Press Release: 'Elixir Pharmaceuticals Names Paul M. Martha, MD as Chief Medical Officer'
|
seekingalpha.com/article/59931-biotech-ipo-elixir-pharm...
seekingalpha.com/article/59931-biotech-ipo-elixir-pharmaceuticals
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - Elixir Pharmaceuticals, Inc., announced today the publication of clinical data highlighting the ability of Glufast(R) (mitiglinide calcium hydrate) monotherapy, or combination therapy with metformin, to manage glucose surges before and after meals.
|
www.drugs.com/clinical_trials/elixir-pharmaceuticals-an...
www.drugs.com/clinical_trials/elixir-pharmaceuticals-announces-clinical-data-american-diabetes-association-conference-1390.html
|
|
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Elixir Pharmaceuticals, Inc., announced today new preclinical data confirming ghrelin antagonism as a potential method for regulating metabolism, decreasing body weight and managing blood glucose.
|
www.drugs.com/clinical_trials/elixir-pharmaceuticals-pr...
www.drugs.com/clinical_trials/elixir-pharmaceuticals-presents-additional-preclinical-data-demonstrating-potential-ghrelin-1194.html
|
|
Elixir Pharmaceuticals is a pharmaceutical company focused on the discovery, development and commercialization of novel pharmaceuticals for the treatment of ... Elixir Pharmaceuticals Picture...
|
www.crunchbase.com/company/elixir-pharmaceuticals
www.crunchbase.com/company/elixir-pharmaceuticals
|
|
2. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control; 3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine;
|
www.bio-medicine.org/medicine-technology/Elixir-Pharmac...
www.bio-medicine.org/medicine-technology/Elixir-Pharmaceuticals-Announces-Clinical-Data-at-American-Diabetes-0AAssociation-Conference-Highlighting-Ability-of-Glufast-to-Maintain-0AGlycemic-Co-224-5/
|
|
